Please login to the form below

Not currently logged in
Email:
Password:

Exviera

This page shows the latest Exviera news and features for those working in and with pharma, biotech and healthcare.

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly?

UK. New entrants such as AbbVie's Viekirax (paritaprevir, ombitasvir and ritonavir) and Exviera (dasabuvir) and Merck &Co's Zepatier (elbasvir/grazoprevir) have also played a role, although Gilead maintains that

Latest news

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    However, AbbVie is set to make an impact in 2015 with the launch of its own interferon-free regimen for hepatitis C, a combination of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics